Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Gary Ingenito Biography and Net Worth

Insider of Catalyst Pharmaceuticals

Dr. Gary Ingenito, M.D., Ph.D., is Chief Medical Officer of Catalyst Pharmaceuticals, Inc. Prior to joining Catalyst, Dr. Ingenito spent more than 25 years in the field of pharmaceutical development; including drugs, biologics, and combination products. During this time, Dr. Ingenito has held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr. Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr. Ingenito has also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and, most recently at Boehringer-Ingelheim Pharmaceuticals, where he served as head of regulatory affairs North America for biosimilars. After obtaining his bachelor of arts degree from The Johns Hopkins University, Dr. Ingenito earned his medical degree at Jefferson Medical College, and a Ph.D. in philosophy from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital.

What is Gary Ingenito's net worth?: The estimated net worth of Gary Ingenito is at least $1.11 million as of June 5th, 2024. Dr. Ingenito owns 51,391 shares of Catalyst Pharmaceuticals stock worth more than $1,114,671 as of November 15th. This net worth evaluation does not reflect any other investments that Dr. Ingenito may own. Additionally, Dr. Ingenito receives a salary of $811,390.00 as Insider at Catalyst Pharmaceuticals. Learn More about Gary Ingenito's net worth.
How old is Gary Ingenito?: Dr. Ingenito is currently 68 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. Learn More on Gary Ingenito's age.
What is Gary Ingenito's salary?: As the Insider of Catalyst Pharmaceuticals, Inc., Dr. Ingenito earns $811,390.00 per year. The highest earning executive at Catalyst Pharmaceuticals is Dr. Steven R. Miller Ph.D., Executive VP, COO & Chief Scientific Officer, who commands a salary of $884,700.00 per year. Learn More on Gary Ingenito's salary.
How do I contact Gary Ingenito?: The corporate mailing address for Dr. Ingenito and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Gary Ingenito's contact information.
Has Gary Ingenito been buying or selling shares of Catalyst Pharmaceuticals?: Gary Ingenito has not been actively trading shares of Catalyst Pharmaceuticals during the past quarter. Most recently, Gary Ingenito sold 80,000 shares of the business's stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $16.16, for a transaction totalling $1,292,800.00. Following the completion of the sale, the insider now directly owns 51,391 shares of the company's stock, valued at $830,478.56. Learn More on Gary Ingenito's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 551,255 shares worth more than $9,231,148.44. The most recent insider tranaction occured on August, 21st when Director David S Tierney sold 15,000 shares worth more than $301,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 8/21/2024.

Gary Ingenito Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2024	Sell	80,000	$16.16	$1,292,800.00	51,391
12/6/2022	Sell	5,918	$16.85	$99,718.30	30,802
6/22/2022	Sell	6,152	$6.61	$40,664.72	22,053
12/7/2021	Sell	3,612	$6.99	$25,247.88
12/22/2020	Sell	3,668	$3.45	$12,654.60	14,666
12/5/2019	Sell	150,000	$4.82	$723,000.00	150,000
11/27/2019	Sell	100,000	$4.66	$466,000.00	100,000
11/21/2019	Sell	100,000	$4.50	$450,000.00	100,000

Gary Ingenito Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.69

$21.53

$22.73

50 Day Range

MA: $20.97

$19.37

$23.93

2 Week Range

Now: $21.69

$13.00

$24.27

Volume

1,226,194 shs

Average Volume

1,194,411 shs

Market Capitalization

$2.59 billion

P/E Ratio

18.38

Dividend Yield

N/A

Beta

0.75

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?

From Golden Crest | Ad

Click Here For Your Free Guide

Gary Ingenito Biography and Net Worth

What is Gary Ingenito's net worth?

How old is Gary Ingenito?

What is Gary Ingenito's salary?

How do I contact Gary Ingenito?

Has Gary Ingenito been buying or selling shares of Catalyst Pharmaceuticals?

Who are Catalyst Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Catalyst Pharmaceuticals?